TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma Therapy - Zurich Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~A) Proven Sars-CoV-2 by PCR and hospitalization for COVID-19 in combination with either (1) or (2):~1. Age ≥50~   AND (at least one):~  * Pre-existing cardiovascular disease~  * Diabetic disease~  * Immunodeficiency/immunosuppression~  * Neoplastic disease~  * COPD or chronic liver disease or chronic renal failure~2. Age ≥18~AND (at least one):~* SpO2 ≤ 94% on room air or requiring supplemental oxygen at screening~* Typical changes on chest x-ray and/or lung-CT scan~* Immunosuppression or neoplastic disease~B) Informed Consent as documented by signature (Appendix Informed Consent Form) of the patient or, in case of inability, of the next relative/care-taking person. In the latter case, an independent doctor will also be involved and her/his signature will be required in order to enrol the patient.~Exclusion Criteria:~1. Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product (FFP)~2. Known IgA deficiency~3. Cytokine Release Syndrome grade ≥3 (see score)\*~4. ARDS~5. Patients already hospitalized in intensive care unit and/or already receiving mechanical ventilation~6. Known or suspected non-compliance, drug or alcohol abuse~7. Previous enrolment into the current study~8. Enrolment of the investigator, his/her family members, employees and other dependent persons~9. Women who are pregnant or breast feeding~10. Intention to become pregnant during the course of the study~11. Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Please note that female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a rheumatic disease.~* Starting treatment with glucocorticoids in a dosage of 7.5 mg prednisone equivalent daily or higher.~* All ethnic groups and races.~Exclusion Criteria:~* Glucocorticoid treatment in the past 12 months (except for 12 weeks preceding the study)~* Primary hyperparathyroidism, hyperthyroidism or hypothyroidism in last year~* Metabolic bone disease~* Creatinine clearance of \< 50 ml/min~* Documented hypercalcemia or hypercalciuria, nephrolithiasis in the last 5 years~* Pregnancy or lactation~* Treatment in the last 12 months with hormone-replacement therapy~* Anabolic steroids, calcitonin, active vitamin D3 analogues, fluoride or bisphosphonates.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed CD20+ B-cell non-Hodgkin's lymphoma No relapsed intermediate or high grade disease eligible for bone marrow or stem cell transplant Intermediate or high grade disease must have received a prior anthracycline containing regimen Low grade disease (with or without prior therapy) felt to be incurable with standard therapy allowed No CNS involvement by lymphoma A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 75,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 3 times upper limit of normal (ULN) AST/ALT less than 3 times ULN Renal: Creatinine no greater than 2 times ULN Cardiovascular: No New York Heart Association class III or IV heart disease No history of angina Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception HIV negative No uncontrolled infection No autoimmune related phenomena No peptic ulcer disease~PRIOR CONCURRENT THERAPY: Biologic therapy: At least 12 months since prior rituximab No prior interleukin-12 No other concurrent immunotherapy Chemotherapy: See Disease Characteristics No prior fludarabine or 2-chlorodeoxyadenosine unless CD4 count normal Recovered from prior chemotherapy No concurrent chemotherapy Endocrine therapy: No concurrent steroid therapy Radiotherapy: No concurrent radiotherapy Surgery: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chlorhexidine Dressings for Hemodialysis Catheter Exit Site Care: Comparative Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be included in the haemodialysis programme in our unit.~* Being a carrier of a tunneled central venous catheter as vascular access.~* Remain on haemodialysis treatment for at least 3 months in our unit.~* Consent to participate in the study.~Exclusion Criteria:~* Allergy or hypersensitivity to chlorhexidine or intolerance to polyurethane dressing~* Active catheter-related infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group chlorhexidine dressing (Type: EXPERIMENTAL): CHG Chlorhexidine Gluconate dressing
- Group solution (Type: OTHER): 2% aqueous-based chlorhexidine solution and covering with a semi-permeable self-adhesive polyurethane dressing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed mantle cell lymphoma (MCL), meeting the following criteria:~  * Diagnosis confirmed by examination of representative material (lymph nodes or bone marrow) together with a typical immunophenotype CD5+, CD23-, sIgM, cyclin D1 nuclear positivity is desirable but not essential~ * Central review of histology will be performed on diagnostic material~ * Molecular or cytogenetic confirmation of diagnosis is not required~* Previously untreated disease at any stage requiring therapy in the opinion of the treating physician~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 3 months~  * Life expectancy not severely limited by other illness~* Creatinine clearance ≥ 30 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during study therapy~* No known serological positivity for HBV, HCV, or HIV~* No concurrent uncontrolled serious medical conditions~* No severe impairment of renal or liver function (alkaline phosphatase, bilirubin or creatinine \> 2.5 times upper limit of normal) not related to lymphoma~* No known hypersensitivity to murine proteins~* No prior malignancy in the past 5 years, except for nonmelanoma skin tumor or curatively resected carcinoma in situ of the uterine cervix~* No history of a psychological illness or condition that, in the opinion of the investigator, may adversely affect compliance with study medication~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine/Cyclophosphamide/Rituximab (Type: EXPERIMENTAL): Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3 Rituximab 375mgs/m2 day 1 iv infusion~Every 28 days
- Fludarabine/Cyclophosphamide (Type: ACTIVE_COMPARATOR): Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3~Every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Advanced (unresectable or metastatic) carcinoid tumor~* Confirmed low-grade or intermediate-grade neuroendocrine carcinoma~* Documented progression of disease within 12 months prior to randomization.~* Measurable disease determined by triphasic computer tomography (CT) scan or magnetic resonance imaging (MRI).~Exclusion criteria:~* Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoma, or small cell carcinoma.~* Hepatic artery embolization within the last 6 months or cryoablation of hepatic metastasis within 2 months of enrollment.~* Previous treatment with mammalian target of rapamycin (mTOR) inhibitors (sirolimus, temsirolimus, everolimus)~* Intolerance or hypersensitivity to octreotide, everolimus, or other rapamycins.~* Severe or uncontrolled medical conditions~* Chronic treatment with corticosteroids or other immunosuppressive agent.~* Other primary cancer within 3 years.~Other protocol-defined inclusion/exclusion criteria applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octreotide+ Everolimus (Type: EXPERIMENTAL): Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.
- Octreotide+ Placebo (Type: PLACEBO_COMPARATOR): Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 75 years old~* male or femalePathologically or cytologically proven esophageal squamous cell carcinoma~* Clinical stage II or stage III~* PG-SGA≧2~* Karnofsky performance score(KPS) ≧70~* Estimated life expectancy of at least 12 weeks~* Hemoglobin≥90.0g/dL,white blood cell count（WBC）≥ 4000 cells/mm³,Platelet count≥100,000 cells/mm³~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 times upper limit of normal,bilirubin normal~* Creatinine normal OR creatinine clearance ≥ 60 mL/min~* Patients have good compliance to treatment and follow-up of acceptance~* Forced expiratory volume in one second（FEV1） ≥ 1.5 litre or ≥ 75% of the reference value~* the functions of the heart, kidney, liver were basically normal, with no chemotherapy and radiotherapy contraindications~Exclusion Criteria:~* Patients with severely bowel function impaired or can not tolerate enteral nutrition~* Patients with serious gastrointestinal obstruction, be unable to take food by mouth and can not / do not want to a feeding tube inserted~* Patients have no risk of malnutrition~* Patients have severe malnutrition (weight loss \>10% or \<30 g/L, BMI\<18.5 kg/m2 or hemoglobin\<90 g/L before the treatment~* Patients who have severe vomiting, gastrointestinal bleeding, intestinal obstruction~* Patients can not tolerate chemotherapy and radiotherapy~* Patients who have distant metastasis~* The primary tumor or lymph node already received surgical treatment (except for biopsy);~* Patient who received radiotherapy for primary tumor or lymph node;~* Patient who received chemotherapy or immunotherapy;~* Patient who suffered from other malignant tumor;~* Patient who have taken other drug test within 1 month;~* Pregnant woman or Lactating Women and Women in productive age who refuse to take contraception in observation period;~* Subject with a severe allergic history or idiosyncratic;~* Subject with severe pulmonary and cardiopathic disease history;~* Refuse or incapable to sign the informed consent form of participating this trial;~* Drug abuse or alcohol addicted;~* Subject with a Personality or psychiatric diseases, people with no legal capacity or people with limited capacity for civil conduct;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): chemoradiotherapy with Enteral Nutrition intervention
- Arm B (Type: PLACEBO_COMPARATOR): chemoradiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, seborrheic dermatitis, asteatotic eczema, neurodermatitis, etc. among eczema/dermatitis for which the observation of pruritus is appropriate)~* Dermal pruritus (generalized dermal pruritus, localized dermal pruritus)~Exclusion Criteria:~* Hypersensitivity to antihistamines or ingredients of a study drug

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desloratadine: Eczema/Dermatitis (Type: EXPERIMENTAL): Participants with eczema/dermatitis receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient antipruritic efficacy and there is no safety concern.
- Desloratadine: Dermal Puritus (Type: EXPERIMENTAL): Participants with dermal pruritus receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient anti-pruritic efficacy and there is no safety concern.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between 3 and 16 years with SDNS~* Minimal Change disease/FSGS/MesPGN/ as per Kidney Biopsy report.~* Estimated glomerular filtration rate (eGFR) \>80 ml/min per 1.73 m2 at study entry.~* Remission at study entry (trace or nil proteinuria, as determined by the dipstick test or \<100 mg/dl for at least 3 days).~* Not received any steroid sparing agent previously.~* Parents willing to give informed written consent.~* Ability to swallow tablet~Exclusion Criteria:~* Known etiology (e.g., lupus erythematosus, IgA nephropathy, amyloidosis, malignancy, other secondary forms of NS)~* Patients with severe leucopenia (leucocytes \<3.0× 1000 cells/mm3), severe anemia (haemoglobin \<8.9 g/dl), thrombocytopenia (platelet \<100.0 × 1000 cells/mm3) or deranged liver function tests (AST or ALT to \>50 IU/L ) at enrolment.~* Known active chronic infection (tuberculosis, HIV, hepatitis B or C) Live vaccination within 1 mo

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus (Type: ACTIVE_COMPARATOR): Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
- Rituximab (Type: EXPERIMENTAL): Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If \>5 B cells per mm3 , it will be measured again after 1 week. If count is still \>5 B cells per mm3, third \& fourth doses of rituximab will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Epilepsy participants from 12 to 17 years of age with:~  * Partial seizures (with or without secondary generalized seizures)~ * Primary generalized Tonic-clonic seizures~Exclusion Criteria:~* Participants previously treated with Fycompa

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Fycompa-treated epilepsy participants (Type: None): Adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-75 years old, male or female, signed informed consent form~2. Advanced NSCLC diagnosed by pathological or clinical physicians~3. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1~4. Participants must have ≥ 1 measurable lesion as defined per RECIST v1.1~5. Participants must have no prior systemic chemotherapy for advanced or metastatic NSCLC~6. Life expectancy ≥ 12 weeks~7. Participants must have adequate organ function~8. Male/female is willing to use a highly effective method of birth control~Exclusion Criteria:~1. Diagnosed with NSCLC but with epidermal growth factor receptor (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation~2. Received any approved systemic anticancer therapy within 28 days prior to the initiation of study treatment~3. Received prior treatment with EGFR inhibitors or ALK inhibitors~4. Received prior therapies targeting programmed cell death protein-1 (PD-1) or programmed cell death protein ligand-1 (PD-L1)~5. With history of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases~6. Clinically significant pericardial effusion~7. Severe infections, active leptomeningeal disease or uncontrolled, untreated brain metastasis~8. Any major surgical procedure ≤ 28 days before randomization~9. Human immunodeficiency virus (HIV) infection~10. Participants with untreated hepatitis B or C virus (HBV/HCV)~11. Active autoimmune diseases or history of autoimmune diseases~12. History of allergic reactions to chemotherapy~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tislelizumab + Platinum + Pemetrexed (Type: EXPERIMENTAL): Tislelizumab 200 milligrams (mg) administered intravenously (IV) once every 3 weeks plus cisplatin 75 mg/m\^2 or carboplatin area under the plasma or serum concentration-time curve (AUC) 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)
- Platinum + Pemetrexed (Type: ACTIVE_COMPARATOR): Cisplatin 75 mg/m\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete